Free Trial

Lexicon Pharmaceuticals Q1 2023 Earnings Report

Lexicon Pharmaceuticals logo
$0.57 +0.22 (+64.13%)
As of 03/28/2025 04:00 PM Eastern

Lexicon Pharmaceuticals EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.17
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Lexicon Pharmaceuticals Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lexicon Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Lexicon Pharmaceuticals Earnings Headlines

Elon Tax Shock?
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
Lexicon stock soars on Novo Nordisk licensing deal
Lexicon announces exclusive license agreement with Novo Nordisk for LX9851
Lexicon announces exclusive license agreement with Novo Nordisk for LX9851
See More Lexicon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexicon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexicon Pharmaceuticals and other key companies, straight to your email.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals (NASDAQ:LXRX), a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

View Lexicon Pharmaceuticals Profile

More Earnings Resources from MarketBeat